DEVELOP is a multicenter, prospective, observational registry of the long-term safety and clinical outcomes of 6070 pediatric patients with inflammatory bowel disease (IBD; Crohn’s disease, ulcerative colitis, or indeterminate colitis) treated with anti-tumor necrosis factor biologics (aTNF) and/or other medical therapies for IBD as part of routine clinical care. DEVELOP has sites in the United States, Canada and the European Union (EU). Our aim was to characterize the incidence of new autoimmune disorders in a pediatric IBD population exposed to aTNF compared to a population exposed only to non-biologics.